Back to Journals » Clinical Ophthalmology » Volume 11

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]

Authors Muñoz Negrete FJ, Lemij HG, Erb C

Received 31 March 2017

Accepted for publication 31 March 2017

Published 11 May 2017 Volume 2017:11 Pages 887—888

DOI https://doi.org/10.2147/OPTH.S138482


Muñoz Negrete FJ, Lemij HG, Erb C. Clinical Ophthalmology. 2017;11:557–566.

On page 557, Abstract, the second sentence “This multicenter, international (Belgium, the Netherlands, and Spain), epidemiological convenience sample survey among patients commencing treatment with preservative-free latanoprost collected data on patient satisfaction with particular regard to tolerability” should read “This multicenter, international (Germany, the Netherlands, and Spain), epidemiological convenience sample survey among patients commencing with preservative-free latanoprost collected data on patient satisfaction with particular regard to tolerability”.

On page 558, Methods section, Inclusion criteria subheading, 1st sentence, the drug name Monoprost® should have been Monopost®.

On page 559, Methods section, Analysis of variables subheading, 2nd paragraph, 1st sentence, the drug name Monoprost® should have been Monopost®.

Read the original article


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]